Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. - Wikidata - wikimedia - TriplyDB

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

http://www.wikidata.org/entity/Q37621547

about

Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness Phosphate binders in chronic kidney disease: a systematic review of recent data.High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients.Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity.Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.Ferric citrate.Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease.Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?Next-generation phosphate binders: focus on iron-based binders.Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?The role of bone in CKD-mediated mineral and vascular disease.Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.Advances in pharmacotherapy for secondary hyperparathyroidism.Novel iron-containing phosphate binders for treatment of hyperphosphatemia.Chronic Kidney Disease-Mineral and Bone Disorder in Asia.A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Treating hyperphosphatemia - current and advancing drugs.Extrarenal effects of FGF23.Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho.Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism.The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease.Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis.Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis.Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats

P2860

Q26786000-A2026609-0DC6-4623-8CAA-373016089FD1 Q31039292-8A042D79-CC96-454F-B52B-A9ED52EE75DD Q33643233-1B66E864-50A8-47BD-BEFE-821F7360C5FD Q34411365-C0717618-B0E3-44D0-89DE-69745BD5AC3C Q35067500-D7573E88-E9C3-41D3-B162-16331015979B Q35106352-FA0B96FC-7C72-402E-8061-0F38E57B4D24 Q36045060-D5A8A0F6-A34E-41FB-9450-0306695444B0 Q36293813-E691E245-5CAF-4EE1-9F95-DA098736AD3B Q36722347-E6A32114-CAE3-499F-9917-376DF4BFF70A Q37069943-158D9648-511E-4EE0-A2FD-E746ED84F90B Q37279085-BFF6F1EB-12AC-4E95-8433-46FE23BE82DC Q38213502-42AF513E-960D-450B-BC6C-5E3F65C1D4F9 Q38223280-72ED907F-4DF8-4A23-AF9B-80EF1F9278EA Q38244314-DE11A938-C611-4302-9CBD-0F0B8BDBED58 Q38542710-F3D0607D-11A6-4782-BC85-E3E4F9B81C78 Q38544533-09C508DC-5ED3-4EB5-901F-7D35DC46C7D0 Q38570622-91E8ECFE-B40A-4A27-A4D6-DCC7744F58E6 Q38635767-40A2F4FE-BAF4-4B80-9C42-2996ACCE434C Q38741675-A0F55640-1457-473E-833A-6B7595601B12 Q38828902-28BA9437-7A3A-4D46-BEF5-94BE88E06937 Q38958363-FE985F8E-1E79-43F4-802E-E4F1D9DBFC37 Q38972469-1CE14DB8-69EC-4FAC-8DF9-4A62C80D742A Q39440902-AD16C8EC-6561-4CD1-B6E8-27F2544B7EFE Q40226740-BCD37F45-AE16-4610-B5C9-6A139D7AF832 Q40478618-300086D0-9130-4C39-AB4B-FFA02EEAD20D Q42233431-2AE0C8C1-70D2-43DB-852F-B35659A35053 Q45976194-3E0EC704-BC88-4F5A-89AA-82EDCCBD889F Q46219047-2D2C6B4C-2A43-407F-B296-C87DFEEB2BE4 Q47101477-C845CD06-A540-4B69-AB7C-036AD1B8D2CF Q47114967-352260E6-5CED-4D05-BC85-8B51266D55C5 Q48226016-A2684C35-BF11-4ABC-8319-A95A5D6B080B Q49908584-88D7A266-1E45-4503-989D-B59BEA41D80F Q50067183-E0E5D4BD-0D4F-4D85-81D7-5CB26D739677 Q51197552-25AA87E2-CAAF-491B-BBDD-0965C99552B3 Q55184664-47BE2281-0502-4302-9D99-C3E51EA82C07 Q56761591-54BA9690-4A3F-4BF7-A5A1-93226E25A2B8 Q57216834-373308B1-4673-4227-9C8A-CEE1EE6A794F

P2860

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

http://www.wikidata.org/entity/Q37621547

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ferric citrate hydrate for the ...... in nondialysis-dependent CKD.

@en

Ferric citrate hydrate for the ...... in nondialysis-dependent CKD.

@nl

type

label

Ferric citrate hydrate for the ...... in nondialysis-dependent CKD.

@en

Ferric citrate hydrate for the ...... in nondialysis-dependent CKD.

@nl

prefLabel

Ferric citrate hydrate for the ...... in nondialysis-dependent CKD.

@en

Ferric citrate hydrate for the ...... in nondialysis-dependent CKD.

@nl

P1433

Q37621547-6D4755F8-498C-4E57-B553-F19AC6C07A0D

P1476

Q37621547-0963850F-03EF-42B8-87E7-BB66DAC48E04

P2093

Q37621547-2B1142F3-874C-474E-AC27-0928A6BA397E

Q37621547-39551B2C-881F-4D63-B600-89F32C0730EC

Q37621547-6D31BED0-4487-4F59-8241-27DE01FA770F

Q37621547-7DEF39B4-94E9-4B38-9CF1-6F2E797C1C50

Q37621547-8C2A7F39-325C-4501-9668-20AFE8F4D8BB

Q37621547-A8DDFAE3-739E-4D20-8831-2590004E4235

Q37621547-E55B5A0B-FB92-4C08-A38B-51EC1A218E55

P2860

Q37621547-0DCD4747-CC12-4A2C-B76C-20A8C24484DE

Q37621547-12CAE9E8-E50F-4344-A6F2-B644D4E3AD64

Q37621547-1ACC7AD8-A651-4A2B-823E-AB53CFAB099A

Q37621547-2257045A-B8EA-4BC9-9173-270C02F846A7

Q37621547-295F41AD-D434-419B-8215-8960A868D01E

Q37621547-2DA35AE6-8944-482C-9119-87605312ECD6

Q37621547-303B4C45-2AC7-4289-987E-A7CFFACC6BDD

Q37621547-3A7DAA2E-DFBB-40A6-B60E-1E052BFB077F

Q37621547-41AB6794-A143-4CD2-A539-92BE8CFBEE8D

Q37621547-4780FB66-706D-4472-98FE-9F2065308767

P304

Q37621547-6CC6CD5B-0A62-49F8-9FA7-FD23C4F6276E

P31

Q37621547-638CC5E4-7F06-435B-B009-91748663D95B

P356

Q37621547-47B643FB-060D-49F5-987D-C7EB56896B51

P433

Q37621547-E21339ED-4808-4F24-9F86-AEEFC8C9FA15

P478

Q37621547-26319785-165C-42AA-B260-F3CFB3CBE587

P50

Q37621547-9E72F7FC-35A2-44E0-8DE4-33E78DCBF2E8

P577

Q37621547-6E9E19F0-83D2-45F9-AFE2-5D14809FD284

P698

Q37621547-15DC88F0-A91D-48AF-BF65-3B7EF1E2C340

P932

Q37621547-4AA0DD52-20F4-40F4-BEFF-858C92F397D3

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Ferric citrate hydrate for the ...... a in nondialysis-dependent CKD

@en

P2093

Geoffrey A Block

http://www.w3.org/2001/XMLSchema#string

Hideki Hirakata

http://www.w3.org/2001/XMLSchema#string

Keitaro Yokoyama

http://www.w3.org/2001/XMLSchema#string

Kenichi Sawada

http://www.w3.org/2001/XMLSchema#string

Masaaki Nakayama

http://www.w3.org/2001/XMLSchema#string

Takashi Akiba

http://www.w3.org/2001/XMLSchema#string

Yuji Kumagai

http://www.w3.org/2001/XMLSchema#string

P2860

Hepcidin: from discovery to differential diagnosis

Oral phosphate binders in patients with kidney failure

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

Serum phosphate and mortality in patients with chronic kidney disease

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Intestinal absorption of aluminium in renal failure.

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

P304

543-552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.05170513

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Masafumi Fukagawa

P577

2014-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24408120

http://www.w3.org/2001/XMLSchema#string

P932

3944759

http://www.w3.org/2001/XMLSchema#string